Onconetix Reports Q1 2026 Progress at Proteomedix AG, Including Two New Peer-Reviewed Publications and Initiation of U.S. Validation Study
Go back to Onconetix Reports Q1 2026 Progress at Proteomedix AG, Including Two New Peer-Reviewed Publications and Initiation of U.S. Validation Study| Oncology Med, Inc. (NASDAQ: ONCO) | Delayed: 0.95 +0.01 (1.06%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.94 | 52 Week High | $0.00 | |||
| Open | $0.89 | 52 Week Low | $0.00 | |||
| Day High | $0.95 | P/E | N/A | |||
| Day Low | $0.88 | EPS | $0.00 | |||
| Volume | 148,204 | |||||
